journal
MENU ▼
Read by QxMD icon Read
search

Cytometry. Part B, Clinical Cytometry

journal
https://www.readbyqxmd.com/read/28732145/evaluation-of-primary-mediastinal-large-b-cell-lymphoma-by-flow-cytometry
#1
Sindhu Cherian, Jonathan R Fromm
BACKGROUND: Primary mediastinal large B cell lymphoma (PMLBCL) is a B cell non-Hodgkin lymphoma (B-NHL) that shows morphologic, immunophenotypic, and genetic similarities to classical Hodgkin lymphoma (CHL). We evaluated the neoplastic and reactive infiltrate of PMLBCL by flow cytometry (FC). METHODS: 24 cases of PMLBCL were retrospectively characterized using FC combinations for B-NHL, T-NHL, and CHL. RESULTS: The CHL assay identified the neoplastic population (NP) in all cases, while the B-NHL assay identified the NP in 18 of 24 cases...
July 21, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28719736/cd326-epcam-testing-by-flow-cytometric-berep4-antibody-is-a-useful-and-rapid-adjunct-to-histopathology
#2
Pranav Dorwal, Helen Moore, Pam Stewart, Barbara Harrison, Julie Monaghan
Flow cytometry has been traditionally used to diagnose leukaemia and lymphoma in peripheral blood, bone marrow, body fluids and tissue samples. The diagnosis of a malignant epithelial tumour is usually made by correlation between histopathologic appearance and the use of immunohistochemical staining. A CE approved BerEP4 antibody (anti-EpCAM, CD326) is available for flow cytometric testing, but has been evaluated predominantly in body fluids in the current literature. In this study, we have evaluated the performance of this antibody in detecting the presence of epithelial cells in tissue samples which have traditionally been reported as CD45 negative cells by flow cytometry...
July 18, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28719730/single-cell-analysis-of-human-tissues-and-solid-tumors-with-mass-cytometry
#3
Nalin Leelatian, Deon B Doxie, Allison R Greenplate, Bret C Mobley, Jonathan M Lehman, Justine Sinnaeve, Rondi M Kauffman, Jay A Werkhaven, Akshitkumar M Mistry, Kyle D Weaver, Reid C Thompson, Pierre P Massion, Mary A Hooks, Mark C Kelley, Lola B Chambless, Rebecca A Ihrie, Jonathan M Irish
No abstract text is available yet for this article.
July 18, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28718205/bcl-2-maturation-pattern-in-t-cells-distinguishes-thymic-neoplasm-hyperplasia-t-lymphoblastic-lymphoma-and-reactive-lymph-nodes
#4
Nicholas Ward, Junaid Baqai, Alexandra Zehnpfennig, Nancy Fine, James Huang, Marc D Smith
Anterior mediastinal biopsies consisting predominantly of small lymphocytes can be a diagnostic challenge, especially in small core biopsies. In these cases, immunophenotyping is often employed using flow cytometry, and/or immunohistochemistry. However, due the overlap in T-cell phenotype between thymic neoplasm/hyperplasia (THY), T lymphoblastic lymphoma (T-LBL) and reactive lymph nodes (RLN), biopsies consisting predominantly of T-cells may still be difficult to differentiate. Previous studies have shown a specific CD3/bcl-2 staining pattern in thymic T cells of humans and mice using flow cytometry...
July 17, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28718199/the-clec12a-receptor-marks-human-basophils-potential-implications-for-minimal-residual-disease-detection-in-myeloid-malignancies
#5
Marie Toft-Petersen, Anne Stidsholt Roug, Trine Plesner, Lene Ebbesen, Gordon D Brown, Line Nederby
BACKGROUND: The transmembrane receptor C-type lectin domain family 12, member A (CLEC12A) is known to be highly expressed on monocytes and neutrophils and is a reliable leukemia associated marker in acute myeloid leukemia. Consequently, detailed knowledge of the various normal cell types expressing this receptor is essential. We have observed CLEC12A to be expressed on CD45lowSSClowCD14-CD123+ basophils in peripheral blood (PB) and in the present study, we aimed at verifying this observation and further delineate the CD45lowSSClowCD14-CD123+CLEC12A+ subpopulation...
July 17, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28646564/the-interference-of-genetic-associations-in-establishing-the-prognostic-value-of-the-immunophenotype-in-acute-myeloid-leukemia
#6
Thomas S van Solinge, Wendelien Zeijlemaker, Gert J Ossenkoppele, Jacqueline Cloos, Gerrit J Schuurhuis
Background In acute myeloid leukemia controversy exists about the role of immunophenotyping of the blasts at diagnosis as a potential prognostic factor. Methods We retrospectively analyzed immunophenotypic marker expression on blasts in relation to genetic aberrancies and survival data of 684 patients. All patients were included in different studies from the HOVON/SAKK Consortium. Results Markers CD2, CD7, CD11b, CD19, CD22 and CD56 all appeared to be associated with one or more established prognostic genetic aberrancies...
June 23, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28618453/data-driven-programmatic-approach-to-analysis-of-basophil-activation-tests
#7
Sarita U Patil, Augustin Calatroni, Michael Schneider, Johanna Steinbrecher, Neal Smith, Cecilia Washburn, Alex Ma, Wayne G Shreffler
BACKGROUND: Conventional data analysis of flow cytometry-based basophil activation testing requires repetitive, labor-intensive analysis that hampers efforts to standardize testing for clinical applications. Using an open-source platform, we developed and implemented a programmatic approach to the analysis of the basophil activation test (BAT) by flow cytometry. METHODS: Using the BÜHLMANN FlowCAST® assay, peripheral blood from peanut allergic patients undergoing oral immunotherapy was incubated with peanut allergens (Arah1, Arah2, Arah6, whole peanut extract) and stained with fluorescent antibodies to CCR3 and CD63 for the development of a data-driven programmatic analysis using Bioconductor and R...
June 15, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28618451/multicenter-comparison-of-cd34-myeloid-cell-count-by-flow-cytometry-in-low-risk-myelodysplastic-syndrome-is-it-feasible
#8
Patricia Font, Dolores Subirá, Sergio Matarraz, Celina Benavente, María Teresa Cedena, Marta Morado, Ana Pérez Corral, José María Bellón, José Luis Díez-Martín
BACKGROUND: Accuracy of bone marrow (BM) blast count in low-risk myelodysplastic syndromes (MDS) still remains a challenge though it is essential for prognosis. We investigated whether the enumeration of CD34+ myeloid cells by flow cytometry immunophenotyping (FCI) could be used as a consistent parameter for clinical MDS studies. METHODS: Six clinical centres entered the study and information on their FCI protocols was recorded. Sixty-seven flow cytometry listmodes from BM samples of patients with low-risk MDS with <5% BM blasts were exchanged among participants in two different rounds...
June 15, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28574201/standardized-high-sensitivity-flow-cytometry-testing-for-paroxysmal-nocturnal-hemoglobinuria-in-children-with-acquired-bone-marrow-failure-disorders-a-single-center-us-study
#9
Rachel E Donohue, Andrea N Marcogliese, Ghadir S Sasa, M Tarek Elghetany, Alka A Redkar, Alison A Bertuch, Choladda V Curry
BACKGROUND: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder that has not been well-documented in children, particularly those with acquired bone marrow failure disorders (ABMFD)-acquired aplastic anemia (AAA) and myelodysplastic syndrome (MDS). Therefore, we sought to determine the prevalence of PNH populations in children with ABMFD. METHODS: PNH testing was performed in children with an ABMFD diagnosis using high sensitivity (≥0...
June 2, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28557280/cd8-expression-in-b-chronic-lymphocytic-leukemia-a-case-of-immuno-phenotypic-aberrancy
#10
Mili Jain, Rashmi Kushwaha, Shailendra Prasad Verma, Uma Shankar Singh, Anil Kumar Tripathi, Madhu Mati Goel, Ashutosh Kumar
Immuno-phenotyping forms an integral part of laboratory work up of Chronic lymphocytic leukemia (CLL). Aberrant antigen expressions are a known phenomenon in leukemic blasts, however cross lineage antigen expression is rarely seen in mature B cell leukemia, the reported percentages varying from 1% to 3% in Europe and North America. CASE DETAILS: We report a case of Rai stage 1 CLL showing aberrant expression of CD8 on flow cytometry. The patient had stable disease at a follow up of 9 months with no requirement of initiation of treatment...
May 30, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28556550/highlights-june-2017
#11
Didier Ebo
No abstract text is available yet for this article.
May 26, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28509416/the-importance-of-cd39-cd43-cd81-and-cd95-expression-for-differentiating-b-cell-lymphoma-by-flow-cytometry
#12
Chandra Chiappin Cardoso, Mariangeles Auat, Iris Mattos Santos-Pirath, Renata Cristina Messores Rudolf-Oliveira, Jessica Pires da Silva, Bárbara Gil Lange, Danielle Siegel, Ana Carolina Rabello de Moraes, Joanita Angela Gonzaga Del Moral, Maria Claudia Santos-Silva
BACKGROUND: B cell lymphomas' (BCL) current diagnosis is usually based on a combination of morphology, immunophenotype, recurrent cytogenetic aberration and clinical features. However, even with these diagnostic tools, a definitive diagnosis can be difficult to achieve. Therefore, the aim of this study was to assess the profile of CD39, CD43, CD81, and CD95 expressions in diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and Burkitt lymphoma (BL) cases. METHODS: To address this issue, we investigated the expression of CD39, CD43, CD81, and CD95 by eight-color flow cytometry in retrospective cases from 2014 to 2016...
May 16, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28493330/improved-panels-for-clinical-immune-phenotyping-utilization-of-the-violet-laser
#13
Mark Ryherd, Matthew Plassmeyer, Connor Alexander, Ines Eugenio, Yuliya Kleschenko, Ariel Badger, Raavi Gupta, Oral Alpan, Søren Ulrik Sønder
BACKGROUND: Clinical diagnostic laboratories are subject to numerous regulations imposed by government agencies. Laboratory developed tests for flow cytometry panels are essentially restricted to the use of analyte-specific reagents (ASR) antibodies. With the advances in clinical flow cytometry systems, there is a trend toward the utilization of blue/red/violet laser flow systems and 8 to 10-color panels. Currently, the selection of commercially available ASR antibodies for the violet laser is very limited...
May 10, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28480599/laboratory-accuracy-improvement-in-the-uk-neqas-leucocyte-immunophenotyping-immune-monitoring-programme-an-eleven-year-review-via-longitudinal-mixed-effects-modeling
#14
John Bainbridge, Wes Rountree, Raul Louzao, John Wong, Liam Whitby, Thomas N Denny, David Barnett
BACKGROUND: The United Kingdom National External Quality Assessment Service (UK NEQAS) for Leucocyte Immunophenotyping Immune Monitoring Programme, provides external quality assessment (EQA) to non-U.S. laboratories affiliated with the NIH NIAID Division of AIDS (DAIDS) clinical trials networks. Selected laboratories are required to have oversight, performance monitoring and remediation undertaken by Immunology Quality Assessment (IQA) staff under the DAIDS contract. We examined whether laboratory accuracy improves with longer EQA participation and whether IQA remediation is effective...
May 8, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28475275/a-qa-program-for-mrd-testing-demonstrates-that-systematic-education-can-reduce-discordance-among-experienced-interpreters
#15
Michael Keeney, Brent L Wood, Benjamin D Hedley, Joseph A DiGiuseppe, Maryalice Stetler-Stevenson, Elisabeth Paietta, Gerard Lozanski, Adam C Seegmiller, Bruce W Greig, Aaron C Shaver, Lata Mukundan, Howard R Higley, Caroline C Sigman, Gary Kelloff, J Milburn Jessup, Michael J Borowitz
BACKGROUND: Minimal residual disease (MRD) in B lymphoblastic leukemia (B-ALL) by flow cytometry is an established prognostic factor used to adjust treatment in most pediatric therapeutic protocols. MRD in B-ALL has been standardized by the Children's Oncology Group (COG) in North America, but not routine clinical labs. The Foundation for National Institutes of Health sought to harmonize MRD measurement among COG, oncology groups, academic, community and government, laboratories. METHODS: Listmode data from post-induction marrows were distributed from a reference lab to seven different clinical FCM labs with variable experience in B-ALL MRD...
May 5, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28449204/an-escca-initiative-on-advanced-analyses-of-monocyte-lineage-using-flow-cytometry
#16
Claude Lambert, Ulrich Sack
No abstract text is available yet for this article.
April 27, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/26566003/vascular-health-profile-predicts-cardiovascular-outcomes-in-patients-with-diabetes
#17
Wade T Rogers, Lifeng Zhang, Scott Welden, Benjamin Krieger, Michael Rickels, Jonni S Moore, Emile R Mohler
BACKGROUND: We previously reported the development of a novel high dimensional cytomic assay, the Vascular Health Profile (VHP) based on measurements of angiogenic circulating hematopoietic stem and progenitor cells (CHSPC(Ang) ) and extracellular vesicles (EVs), that discovered a unique signature, differentiating the vascular status of diabetics and normal healthy controls. Here, we present data from a 3-year follow-up to evaluate the power of the VHP to identify individuals at risk for cardiovascular (CV) events...
July 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28504481/comprehensive-mass-cytometry-analysis-of-cell-cycle-activation-and-co-inhibitory-receptors-expression-in-cd4-t-cells-from-healthy-and-hiv-infected-individuals
#18
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28431200/the-utility-of-flow-cytometry-in-differentiating-nk-t-cell-lymphoma-from-indolent-and-reactive-nk-cell-proliferations
#19
Sanjay de Mel, Jenny Bei Li, Muhammad Bilal Abid, Tiffany Pooi Ling Tang, Hui Ming Tay, Wen Chang Ting, Li Mei Poon, Tae Hoon Chung, Benjamin Mow, Allison Tso, Kiat Hoe Ong, Wee Joo Chng, Te Chih Liu
BACKGROUND: The WHO defines three categories of NK cell malignancies; extra nodal NK/T cell lymphoma (NKTCL), aggressive NK cell leukemia, and the provisional entity chronic lymphoproliferative disorder of NK cells (CLPD-NK). Although the flow cytometric (FC) phenotype of CLPD-NK has been described, studies on FC phenotype of NKTCL are limited. To the best of our knowledge ours is the first study to compare the phenotype of NKTCL, CLPD-NK, reactive NK lymphocytosis (RNKL), and normal NK cells using eight color (8C) FC...
April 21, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28378896/a-comprehensive-assessment-of-immunophenotyping-performed-in-cryopreserved-peripheral-whole-blood
#20
Chris P Verschoor, Vikas Kohli, Cynthia Balion
BACKGROUND: Monitoring the frequency and phenotype of white blood cell subsets using flow cytometry (immunophenotyping) has proven to be an incredibly powerful tool in the assessment of health. Although improved technologies have aided in the practical implementation of immunophenotyping in clinical and epidemiological studies, the transportation of blood from the site of collection to a central laboratory for analysis within a reasonable timeframe may not be feasible. Hence, the purpose of the following study was to investigate the validity of cryopreserved whole blood as a simple to prepare and cost-effective biospecimen for multi-colour immunophenotyping in a large epidemiological study-namely, The Canadian Longitudinal Study on Aging (CLSA)...
April 5, 2017: Cytometry. Part B, Clinical Cytometry
journal
journal
40908
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"